Grifols, S.A. Q2 2026 Earnings Recap

GRF.MC Q2 2026 July 30, 2026

Get alerts when GRF.MC reports next quarter

Grifols shares rose 5.2% following Q2 earnings, buoyed by biopharma revenue growth that surpassed expectations and a cautious but confident outlook on operational execution and pipeline progress.

Earnings Per Share Miss

$0.22 vs $0.23 est.

-3.4% surprise

Revenue Miss

1853966000 vs 1886990000 est.

-1.8% surprise

Market Reaction

1-Day -4.05%

5-Day -2.7%

See GRF.MC alongside your other holdings

Add to your portfolio — free

Key Takeaways

Q2 adjusted EBITDA margin improved to 25.2%, supporting profitability amid disciplined commercial execution.
Biopharma segment grew 5.4%, driving overall 2.6% constant currency revenue growth in H1 2026.
Free cash flow rose by approximately €100 million in the first half, reflecting operational discipline and working capital efficiency.
New product launches and ongoing Phase III trials (e.g., GAMUNEX-C, XEMBIFY) indicate pipeline advancement in immunoglobulin and protein therapies.
Strategic initiatives include expanding plasma collection in Egypt and Canada and preparations for potential IPO of the U.S. Biopharma unit.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit GRF.MC on AllInvestView.

Previous Q1 2026